Survodutide

Description

Chemical Identity

Survodutide analytical reference compound. Molecular weight 4231.62 Da. Also known as: BI 456906. Research status: Phase3.

Research Overview

Survodutide (BI 456906) is a dual glucagon receptor (GCGR) and GLP-1 receptor agonist developed by Boehringer Ingelheim currently in Phase 3 clinical trials for obesity and MASH/NASH. It uniquely combines GLP-1 signaling for appetite suppression with glucagon signaling for increased energy expenditure.

The GLP-1 receptor component of survodutide’s mechanism operates through well-characterized pathways shared with approved GLP-1 receptor agonists. Upon binding to GLP-1R, a class B G-protein coupled receptor expressed on pancreatic beta cells, neurons in the hypothalamus and brainstem, and gastrointestinal tract cells, survodutide activates Gs-alpha signaling and downstream cAMP-dependent pathways.

In the central nervous system, GLP-1R activation in the arcuate nucleus, paraventricular nucleus, and nucleus of the solitary tract modulates appetite-regulating circuits, suppressing hunger and promoting satiety. These effects are mediated through inhibition of orexigenic (appetite-stimulating) NPY/AgRP neurons and activation of anorexigenic POMC/CART neurons. GLP-1R activation also slows gastric emptying via vagal afferent signaling, contributing to reduced caloric intake per meal.

The COURAGE trial was a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study evaluating survodutide in adults with overweight or obesity (BMI 28 or greater) without diabetes. The trial enrolled 387 participants randomized to one of four survodutide dose groups (0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg once weekly, with dose escalation) or placebo for 46 weeks.

Key published studies on Survodutide include: “Efficacy and Safety of Survodutide (BI 456906), a Dual Glucagon Receptor/GLP-1 Receptor Agonist, in Adults with Overweight or Obesity: A Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Trial (COURAGE)” (The Lancet, 2024); “Survodutide for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis: A Randomised, Double-Blind, Placebo-Controlled Phase 2b Trial” (The Lancet, 2024). These findings should be interpreted within the context of the experimental models and conditions described in each publication.

Research Context

Survodutide (development code BI 456906) is a novel dual agonist peptide that activates both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It is being developed by Boehringer Ingelheim and Zealand Pharma and is currently in Phase 3 clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). Survodutide represents a pharmacological approach that combines the appetite-suppressing and glucose-lowering effects of GLP-1 receptor agonism with the energy expenditure-enhancing and lipid-mobilizing effects of glucagon receptor agonism.

The dual agonist concept for survodutide emerged from the recognition that while GLP-1 receptor agonists (such as semaglutide and liraglutide) achieve weight loss primarily through appetite reduction and slowed gastric emptying, they do not substantially increase energy expenditure. Glucagon, traditionally viewed as a counter-regulatory hormone opposing insulin’s metabolic effects, has potent thermogenic and lipolytic properties that can complement GLP-1-mediated caloric reduction. However, glucagon receptor agonism alone would be expected to raise blood glucose levels through hepatic glycogenolysis and gluconeogenesis. By combining both receptor activities in a single molecule, survodutide aims to achieve synergistic weight loss and metabolic improvement while using the glucose-lowering effect of GLP-1R activation to offset the hyperglycemic potential of glucagon signaling.

Survodutide is designed as a peptide-based molecule with relative activity ratios favoring glucagon receptor activation approximately 4-5 fold over GLP-1 receptor activation. This glucagon-favoring ratio distinguishes it from other dual and triple agonists in development, such as tirzepatide (GIP/GLP-1 dual agonist) and retatrutide (GIP/GLP-1/glucagon triple agonist), which employ different receptor combinations and activity ratios. The molecule has been engineered for once-weekly subcutaneous administration through structural modifications that extend its pharmacokinetic half-life.

Specifications

Each lot is accompanied by a Certificate of Analysis (COA) documenting purity, identity, and endotoxin testing results.

Research Applications

Survodutide reference compound has been documented in the published scientific literature across the following in vitro and preclinical research areas:

• GLP-1 Receptor Agonism
• Glucagon Receptor Agonism
• Synergistic Dual Mechanism
• Phase 2 COURAGE Trial (Obesity)
• Phase 2b MASH Trial
• Phase 3 Program
• Safety and Tolerability Profile
• Comparison with Other Incretin Therapies

Researchers are advised to consult the primary literature for detailed experimental protocols, concentrations, and conditions relevant to their specific area of investigation involving Survodutide.

Storage and Handling

Survodutide is supplied as a lyophilized powder and should be stored at -20°C upon receipt for long-term stability. Protect from light, moisture, and repeated temperature fluctuations. Allow the sealed vial to equilibrate to room temperature before opening to prevent condensation and moisture absorption.

For reconstitution, add sterile water or an appropriate buffer slowly along the vial wall to avoid foaming. Gently swirl to dissolve — do not vortex. Reconstituted Survodutide solutions should be stored at 2-8°C and used within 30 days. Aliquoting is recommended to minimize freeze-thaw cycles. Consult the Safety Data Sheet (SDS) for detailed handling and disposal guidance.

For laboratory research use only (in vitro). Not for human or animal use. Not for diagnostic, therapeutic, or clinical purposes. Survodutide is supplied as an analytical reference compound for use by qualified research personnel at accredited institutions. Prescott Bio Canada does not provide guidance on administration, dosing, or use in living organisms.